Product Update: Latest evolution of BioVolume® sets new standard for subcutaneous tumour monitoring

Product Update: Latest evolution of BioVolume® sets new standard for subcutaneous tumour monitoring

Post by: Andrew Smith, Head of BioVolume Commercialisation

During the past few weeks we’ve been busy unveiling the latest evolution of our BioVolume subcutaneous tumour monitoring solution in Europe and the US. Combining 3D imaging with thermography, BioVolume is setting a new standard in the quest for accurate, reproducible data and better science.

By incorporating thermal imaging we’ve been able to drive significant measurement improvements and we were delighted to have the opportunity at the AALAS National Meeting in Baltimore to share highlights from the research we have conducted with our major pharmaceutical industry partner. The latest results of segmentation are very promising, with over 90% of points within +/-3mm of callipers. We are getting some great results in relation to inter-operator variability and precision too (stay tuned for our next blog update!).

Over 200 people attended our presentation on ‘Championing the 3Rs with 3D imaging and AI in Cancer Research’ which Dr Juan Delgado delivered as part of the main conference platform and myself shared with a keen audience attending the show’s technical seminar programme.

The feedback we have received on the developments we have made with the product has been very positive and delegates at the conference were very interested in both the work we have been doing to improve measurement accuracy and traceability as well as our work in monitoring tumour condition including redness, pallor and ulceration and how we can use machine learning algorithms to associate different tumour conditions and their outcomes.

Delegates were impressed with BioVolume’s potential to make trials more effective by removing human bias and the major impact a change in operator can have on a trial. They also recognised its potential to ensure greater animal welfare in adherence with the 3Rs (Refinement, Reduction and Replacement) while enabling new cancer drugs to be brought to market faster by reducing the length of preclinical trials. The cloud platform also received good feedback, allowing all study partners to access trial data as and when needed.

One of the interesting common themes at AALAS this year was the desire for collaboration in the industry and in the laboratory equipment supply chain to deliver the lab of the future. This will continue to be an important consideration for our product roadmap and the work that we are doing to ensure that BioVolume can be easily integrated with mice tagging solutions and other digital laboratory platforms to create an end-to-end solution providing accurate auditable data and improved animal welfare.

Our attendance at NCRI Cancer Conference in Glasgow earlier this month gave us another opportunity to meet existing and new organisations interested in using BioVolume in their labs and to showcase the benefits of digital transformation in preclinical research on a platform dedicated exclusively to cancer research. The NCRI conference is the UK’s largest forum sharing the latest advances in cancer research and it was great to be part of the community dedicated to advancing cancer research and improving and saving lives. Again, we received very positive feedback on how BioVolume will be a step change for monitoring subcutaneous tumours in preclinical research.

And finally, just yesterday at the World Preclinical Congress Europe, we presented a case study outlining how AI and machine learning and they can be applied to the drug discovery process – many industry experts were excited about the findings and the impacts the application will have on improving preclinical research.

No Comments

Post A Comment
Contact Us
Thanks for your message
We'll be in touch shortly

captcha

captcha

7


captcha